Dr. Mario Sznol, MD

Dr. Sznol practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Sznol's NPI, 1073501748, was assigned on October 7, 2005. Dr. Sznol graduated from Baylor College Of Medicine in 1982. Dr. Sznol holds Connecticut license 0358548.

Dr. Sznol's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Sznol's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Sznol is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Sznol to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sznol practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Sznol's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Sznol is licensed in Connecticut.

CMS data shows 461 Medicare services from Dr. Sznol across 3 procedure codes in 2024, all of them office visits, for 123 Medicare patients. Medicare paid $29,736 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 123 Medicare patients who saw Dr. Sznol in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sznol's median patient age at 74, with 30% women.

In 2024, Dr. Sznol wrote 333 Medicare Part D claims for 45 patients. 48% of them were for generic drugs. CMS names the drug for 243 of them, across 11 drugs with 11 or more claims each, at $2,730,165 in total drug cost. In 2023, CMS named 185 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Sznol for performance year 2024, reported as part of a group. Dr. Sznol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sznol as offering telehealth.

Dmand AI links 131 papers to Dr. Sznol, published from 2010 to 2025. 2017 was the busiest year, with 15. The most frequent topics are Melanoma, Nivolumab and Immunotherapy. Dr. Sznol has published most often in J Clin Oncol. Dr. Sznol's most frequent co-authors are Harriet Margot Kluger, MD, David Francis McDermott, MD and Michael B. Atkins, MD.

Dmand AI links Dr. Sznol to 9 clinical trials, 4 of them phase 1 studies. Conditions studied include Carcinoma, Renal Cell, Melanoma and Brain Neoplasms. Open Payments lists research payments to Dr. Sznol that name 1 trial.

CMS Open Payments shows 261 general payments to Dr. Sznol from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Bristol-Myers Squibb Company paid the most, $45,523. It also lists 19 research payments totaling $14,502 from 2020 to 2025, naming 1 clinical trial.

Dr. Sznol graduated from Baylor College Of Medicine in 1982.